Inhibition of sumoylation prevents experimental fibrosis

Annals of the Rheumatic Diseases

Volumn 71, Issue 11, 2012, Pages 1904-1908

  Khodzhigorova, Aisa ^a   Distler, Alfiya ^a   Lang, Veronika ^a   Dees, Clara ^a   Schneider, Holm ^a   Beyer, Christian ^a   Gelse, Kolja ^a   Distler, Oliver ^b   Schett, Georg ^a   Distler, Jörg H W ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BLEOMYCIN; COLLAGEN; PROTEIN UBC9; SMAD3 PROTEIN; SMALL INTERFERING RNA; SUMO 1 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; FIBROSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; MOUSE; MYOFIBROBLAST; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKIN BIOPSY; SKINFOLD THICKNESS; SUMOYLATION; SYSTEMIC SCLEROSIS;

ADOLESCENT; ADULT; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLASTS; FIBROSIS; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KERATINOCYTES; MALE; METHOTREXATE; MICE; MIDDLE AGED; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, SMALL INTERFERING; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SKIN; SMAD3 PROTEIN; SUMO-1 PROTEIN; SUMOYLATION; UBIQUITIN-CONJUGATING ENZYMES; YOUNG ADULT;

EID: 84867399017     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-201746     Document Type: Article

References (20)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360:1989-2003.
2. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007;117:557-67. (Pubitemid 46348510)
3. Huber LC, Stanczyk J, Jungel A, et al. Epigenetics in inflammatory rheumatic diseases. Arthritis Rheum 2007;56:3523-31. (Pubitemid 350100685)
4. Wilkinson KA, Henley JM. Mechanisms, regulation and consequences of protein SUMOylation. Biochem J 2010;428:133-45.
5. Wang Y, Dasso M. SUMOylation and deSUMOylation at a glance. J Cell Sci 2009;122:4249-52.
6. Driscoll JJ, Dechowdhury R. Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy. Target Oncol 2010;5:281-89.
7. Huber LC, Distler JH, Moritz F, et al. Trichostatin a prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. Arthritis Rheum 2007;56:2755-64. (Pubitemid 47237295)
8. Zhou X, Lin W, Tan FK, et al. Decreased catalytic function with altered sumoylation of DNA topoisomerase I in the nuclei of scleroderma fibroblasts. Arthritis Res Ther 2011;13:R128.
9. Jungel A, Distler JH, Gay S, et al. Epigenetic modifications: novel therapeutic strategies for systemic sclerosis? Expert Rev Clin Immunol 2011;7:475-80.
10. Imoto S, Ohbayashi N, Ikeda O, et al. Sumoylation of Smad3 stimulates its nuclear export during PIASy-mediated suppression of TGF-beta signaling. Biochem Biophys Res Commun 2008;370:359-65.
11. Kang JS, Saunier EF, Akhurst RJ, et al. The type I TGF-beta receptor is covalently modified and regulated by sumoylation. Nat Cell Biol 2008;10:654-64. (Pubitemid 351772931)
12. Lin X, Liang M, Liang YY, et al. Activation of transforming growth factor-beta signaling by SUMO-1 modification of tumor suppressor Smad4/DPC4. J Biol Chem 2003;278:18714-19. (Pubitemid 36799251)
13. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5. (Pubitemid 18073738)
14. Horn A, Kireva T, Palumbo-Zerr K, et al. Inhibition of hedgehog signaling prevents experimental fibrosis and induces regression of established fibrosis. Ann Rheum Dis 2012;71:785-9.
15. Palumbo K, Zerr P, Tomcik M, et al. The transcription factor JunD mediates transforming growth factor {beta}-induced fibroblast activation and fibrosis in systemic sclerosis. Ann Rheum Dis 2011;70:1320-6.
16. Akhmetshina A, Palumbo-Zerr K, Dees C, et al. Activation of canonical Wnt signalling is required for TGF-β mediated fibrosis. Nature Commun 2012;13:735.
17. Beyer C, Reich N, Schindler SC, et al. Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis. Ann Rheum Dis 2012;71:1019-26.
18. Beyer C, Schramm A, Akhmetshina A, et al. beta-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis. Ann Rheum Dis 2012;71:761-7.
19. Lee PS, Chang C, Liu D, et al. Sumoylation of Smad4, the common Smad mediator of transforming growth factor-beta family signaling. J Biol Chem 2003;278:27853-63. (Pubitemid 36899978)
20. Long J, Wang G, He D, et al. Repression of Smad4 transcriptional activity by SUMO modification. Biochem J 2004;379:23-9. (Pubitemid 38491355)